Course Of Hemangiomas Research Articles

PARTICULARITIES OF THE COURSE AND TREATMENT HEMANGIOMAS OF DIFFERENT MORPHOLOGICAL TYPES IN CHILDREN AND THEIR ASSOCIATION WITH SOLUBLE FORMS OF FAS AND FASL

The article discusses analysis of examinations and treatment results 100 children with hemangiomas different localizations on the different stages of existence. The study included patients of different ages, from birth to 6 years. Importance of primary assessment of severity and activity of hemangioma`s, for the choice of treatment, was considered. Correlation between clinical course of hemangiomas and soluble Fas/FasL was analyzed. The object of the research: Clinical course of hemangiomas of different morphological types, soluble form of Fas and FasL in the serum of patients with hemangiomas. Investigated problem: Improving the results of treatment of hemangiomas in children. The main scientific results: Predicting the course of hemangiomas in children allows to determine the need for treatment at different stages of their existence, as well as to carry out timely correction of the prescribed treatment to achieve good cosmetic and functional results. The area of practical use of the research results: Department of Pediatrics, Pediatric Surgery, Dermatology. Innovative technological product: Defined characteristics will help in predicting the course of hemangiomas and the effectiveness of their treatment. Scope of the innovative technological product: Clinical pediatric practice.

Serum Levels of Vascular Endothelial Growth Factor and Basic Fibroblastic Growth Factor in Children with Hemangiomas and Vascular Malformations—Preliminary Report

Impaired balance between proangiogenic and antiangiogenic factors has been implicated in the development of hemangiomas. Elevated vascular endothelial growth factor serum levels and basic fibroblastic growth factor urine levels in patients with proliferating hemangiomas were reported. However, whether these growth factors can be used for the differential diagnosis of vascular anomalies or assessment of the clinical course of hemangiomas has yet to be determined. We report here our preliminary results of serum vascular endothelial growth factor and basic fibroblastic growth factor levels as an aid in the diagnosis of hemangiomas and in the follow up of patients with this lesion. Twenty two children with infantile hemangioma (13 with proliferating hemangiomas, nine with involuting lesions), five children with vascular malformations, and 25 healthy children study group. Vascular endothelial growth factor and basic fibroblastic growth factor serum levels were analyzed by an ELISA assay. The serum vascular endothelial growth factor concentrations in children with proliferating hemangiomas were significantly higher than in patients with involuting hemangiomas, vascular malformations and healthy patients. The serum basic fibroblastic growth factor concentrations were low and similar in all patients with no statistical correlation between study groups. We concluded that (i) ELISA can easily determine vascular endothelial growth factor concentrations in different phases of hemangioma growth and help distinguishing them from vascular malformations. (ii) A potential role for vascular endothelial growth factor in the pathophysiology of hemangiomas is probable.

Management of Cutaneous Juvenile Hemangiomas

Past descriptions of vascular lesions often confused vascular malformations and hemangiomas using interchangeable definitions which led to inappropriate treatment and inconsistency in the medical literature. The work of Mulliken and Glowacki systematically delineated the difference between hemangiomas and the multiple varieties of vascular malformations. Hemangiomas are in fact as the suffix "oma" suggests true tumors exhibiting cellular proliferation on histology. Additionally, treatment has been clouded by numerous reports in the literature of near universal complete spontaneous resolution and conversely arguments that every lesion demands treatment. More recently, thoughtful studies of the natural course of hemangiomas have been completed, algorithms for intervention versus observation proposed, and effective safe treatment plans devised. The following article will be presented in two sections. The first section will review the diagnosis and natural history of hemangiomas as appreciated in modern literature and compare this to a review of historical articles. This information will then be used to describe a rational and thoughtful algorithm for observation or intervention and recommend appropriate treatment options. Special emphasis will be given to surgical technique and several cases of late involuting hemangiomas of the face will be presented.

An Aesthetic Approach to Facial Hemangiomas

Hemangiomas are the most common tumor of infancy and childhood, affecting approximately 10% of infants by the age of 1 year. The diagnosis can nearly always be made by the patient's history and findings on physical examination. Prior to the classification system outlined by Mulliken and Glowacki, the natural course of hemangiomas was poorly understood and treatment was inconsistent, ranging from benign neglect to deforming surgical intervention. However, with an improved understanding of the natural course of hemangiomas, as well as advances in anesthesia, laser technology, medical therapy, and surgical methods, an aesthetic approach to facial hemangiomas was developed by the senior author (E.F.W.) and is reviewed in this article.

Spontaneous course of hemangiomas: facts and speculations

International Journal of DermatologyVolume 37, Issue 2 p. 101-102 Spontaneous course of hemangiomas: facts and speculations Peter Van De Kerkhof, MD, Peter Van De Kerkhof, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this authorMichette De Rooij, MD, Michette De Rooij, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this authorPeter Steijlen, MD, Peter Steijlen, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this author Peter Van De Kerkhof, MD, Peter Van De Kerkhof, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this authorMichette De Rooij, MD, Michette De Rooij, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this authorPeter Steijlen, MD, Peter Steijlen, MD The Department of Dermatology, University Hospital Nijmegen, The NetherlandsSearch for more papers by this author First published: 05 January 2002 https://doi.org/10.1046/j.1365-4362.1998.00343.xCitations: 5 Peter C.M.Van De Kerkhof MD Department of Dermatology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume37, Issue2February 1998Pages 101-102 RelatedInformation

Congenital hemangioma: Evidence of accelerated involution

OBJECTIVE: To study the course of hemangiomas that proliferate in utero, are fully grown at birth, and begin to regress during early infancy. DESIGN: We analyzed retrospectively 31 infants with congenital hemangioma seen at Tarnier-Cochin Hospital (Paris) and Children's Hospital (Boston). Diagnosis was made by clinical and radiologic examination and, if necessary, by biopsy. Age, gender, location, appearance, and evolution were noted for each infant. RESULTS: Only 3 of 23 congenital hemangiomas were diagnosed in utero by ultrasonography. The three most common morphologic forms were raised violaceous tumor with ectatic veins (n = 8), raised grayish tumor with multiple tiny telangiectasias, surrounded by a pale halo (n = 8), and flat infiltrative tumor with violaceous overlying skin (n = 5). Two congenital hemangiomas had associated thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon). All the untreated congenital hemangiomas (n = 24) regressed by the time the infants were 14 months of age, leaving either atrophic skin or extra skin. Seven congenital hemangiomas required therapy for complications: three tumors responded to systemic corticosteroid administration and four were resected. CONCLUSION: Hemangiomas can proliferate in utero and manifest as fully developed tumors at birth. These congenital hemangiomas can regress rapidly. This phenomenon raises new questions about the pathogenesis of this tumor. (J P EDIATR 1996;128:329-35)